Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.09
-0.3067-0.74%
Post-market: 41.500.4110+1.00%19:30 EDT
Volume:29.56K
Turnover:1.22M
Market Cap:1.19B
PE:- -
High:41.29
Open:41.29
Low:41.01
Close:41.40
52wk High:42.87
52wk Low:27.30
Shares:28.85M
Float Shares:28.85M
Volume Ratio:1.37
T/O Rate:0.10%
Dividend:0.42
Dividend Rate:1.03%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Sep 15

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Sep 15

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Sep 14

Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months

MT Newswires Live
·
Sep 14